Asthma persistence versus progression: Does airway smooth muscle function predict irreversible airflow obstruction?

Allergy and Asthma Proceedings

Volumn 30, Issue 2, 2009, Pages 103-108

  Panettieri Jr , Reynold A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Airway remodeling; Allergy; Bronchoconstriction; Bronchodilation; Corticosteroid insensitivity; Corticosteroids; Cytokine; Guidelines; Inflammation; Resistance

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; FENOTEROL; FLUTICASONE PROPIONATE; INTERFERON; MONTELUKAST; SALBUTAMOL; SALMETEROL; TUMOR NECROSIS FACTOR ALPHA; CORTICOSTEROID; GAMMA INTERFERON; IMMUNOLOGIC FACTOR;

AIRWAY OBSTRUCTION; ASTHMA; BREATHING MUSCLE; CONFERENCE PAPER; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DISEASE COURSE; DRUG MECHANISM; DRUG SENSITIVITY; GENOTYPE; HUMAN; IMMUNOMODULATION; LUNG FUNCTION; MUSCLE FUNCTION; PHENOTYPE; RESPIRATORY TRACT INFLAMMATION; SMOOTH MUSCLE; TREATMENT RESPONSE; BRONCHOSPASM; CELL CULTURE; DRUG EFFECT; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RESPIRATORY TRACT MUCOSA; REVIEW; SMOOTH MUSCLE FIBER; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AIRWAY OBSTRUCTION; ASTHMA; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; CELLS, CULTURED; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; LUNG; MYOCYTES, SMOOTH MUSCLE; PROGNOSIS; RESPIRATORY MUCOSA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650489576     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3202     Document Type: Conference Paper

References (55)

1. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: The effects of asthma and cigarette smoking. Am J Respir Crit Care Med 171:109-114, 2005.
2. Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339:1194-1200, 1998.
3. Peat JK, Woolcock AJ, and Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 70:171-179, 1987.
4. Phelan PD, Robertson CF, and Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol 109:189-194, 2002.
5. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 349:1414-1422, 2003.
6. Ulrik CS. Outcome of asthma: Longitudinal changes in lung function. Eur Respir J 13:904-918, 1999.
7. Frieri M. Asthma concepts in the new millennium: Update in asthma pathophysiology. Allergy Asthma Proc 26:83-88, 2005.
8. Frieri M. Advances in the understanding of allergic asthma. Allergy Asthma Proc 28:614-619, 2007.
9. Bergeron C, and Boulet LP. Structural changes in airway diseases: Characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 129:1068-1087, 2006.
10. Boulet L, Belanger M, and Carrier G. Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction. Am J Respir Crit Care Med 152:865-871, 1995.
11. Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 24:122-128, 2004.
12. Capetandes A, Zhuang M, Haque FN, et al. Vascular endothelial growth factor is increased by human pulmonary cells stimulated with Dermatophagoides sp. extract. Allergy Asthma Proc 28:324-330, 2007.
13. Lazaar AL, and Panettieri RA Jr. Is airway remodeling clinically relevant in asthma? Am J Med 115:652-659, 2003.
14. National Institutes of Health (NIH). Expert panel report 3: Guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute, NIH U.S. Department of Health and Human Services, NIH Publication No. 07-4051, 2007.
15. Frieri M, and Capetandes A. The effect of enantiomers of beta-agonists on myofibroblast-derived vascular endothelial growth factor and other matrix components in the presence of dustmite extract. Allergy Asthma Proc 29:182-188, 2008.
16. Puglisi G, Horne N, Huang YC, and Frieri M. Transforming growth factor beta 1 (TGF-β1) production and expression from ragweed stimulated human alveolar epithelial cells (A549): Modulation by budesonide, formoterol, and levalbuterol. Ann Allergy Asthma Immunol 94:165, Abstract P148, 2005 (Abs).
17. Panettieri RA Jr, and Kotlikoff MI. Cellular and molecular mechanisms regulating airway smooth muscle cell physiology and pharmacology. In Pulmonary Diseases and Disorders, 3rd ed. Fishman AP, Elias JA, Fishman JA, et al. (Eds). New York: McGraw-Hill, 107-117, 1998.
18. Stewart AG, Tomlinson PR, and Wilson JW. Beta 2-adrenoceptor agonist-mediated inhibition of human airway smooth muscle cell proliferation: Importance of the duration of beta 2-adrenoceptor stimulation. Br J Pharmacol 121:361-368, 1997.
19. Tomlinson PR, Wilson JW, and Stewart AG. Inhibition by salbutamol of the proliferation of human airway smooth muscle cells grown in culture. Br J Pharmacol 111:641-647, 1994.
20. Tomlinson PR, Wilson JW, and Stewart AG. Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: Relationship to elevated cAMP levels. Biochem Pharmacol 49:1809-1819, 1995.
21. Stewart AG, Harris T, Fernandes DJ, et al. β2-adrenergic receptor agonists and cAMP arrest human cultured airway smooth muscle cells in the G1 phase of the cell cycle: Role of proteasome degradation of cyclin D1. Mol Pharmacol 56:1079-1086, 1999.
22. Musa NL, Ramakrishnan M, Li J, et al. Forskolin inhibits cyclin D1 expression in cultured airway smooth-muscle cells. Am J Respir Cell Mol Biol 20:352-358, 1999.
23. Fernandes D, Guida E, Koutsoubos V, et al. Glucocorticoids inhibit proliferation, cyclin D1 expression, and retinoblastoma protein phosphorylation, but not activity of the extracellular-regulated kinases in human cultured airway smooth muscle. Am J Respir Cell Mol Biol 21:77-88, 1999.
24. Bonacci JV, Schuliga M, Harris T, et al. Collagen impairs glucocorticoid actions in airway smooth muscle through integrin signalling. Br J Pharmacol 149:365-373, 2006.
25. Huang YC, Leyko B, and Frieri M. Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann Allergy Asthma Immunol 95:443-451, 2005.
26. Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 87:1541-1546, 1991.
27. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326:298-304, 1992.
28. Frieri M, Therattil J, Wang SF, et al. Montelukast inhibits interleukin-5 mRNA expression and cysteinyl leukotriene production in ragweed and mite-stimulated peripheral blood mononuclear cells from patients with asthma. Allergy Asthma Proc 24:359-366, 2003.
29. Lazaar AL, Albelda SM, Pilewski JM, et al. T lymphocytes adhere to airway smooth muscle cells via integrins and CD44 and induce smooth muscle cell DNA synthesis. J Exp Med 180:807-816, 1994.
30. Liu AH. Endotoxin exposure in allergy and asthma: Reconciling a paradox. J Allergy Clin Immunol 109:379-392, 2002.
31. Leung DY, and Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111:3-22, 2003.
32. Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 318:635-641, 1985.
33. Ammit AJ, Hoffman RK, Amrani Y, et al. TNFα-induced secretion of RANTES and IL-6 from human airway smooth muscle cells: modulation by cAMP. Am J Respir Cell Mol Biol 23:794-802, 2000.
34. John M, Hirst SJ, Jose PJ, et al. Human airway smooth muscle cells express and release RANTES in response to T helper 1 cytokines. Regulation by T helper 2 cytokines and corticosteroids. J Immunol 158:1841-1847, 1997.
35. Pype JL, Dupont LJ, Menten P, et al. Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines. Am J Respir Cell Mol Biol 21:528-536, 1999.
36. 2-agonists and corticosteroids. FASEB J 115:261-269, 2001.
37. Saunders MA, Mitchell JA, Seldon PM, et al. Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: Suppression by dexamethasone. Br J Pharmacol 120:545-546, 1997.
38. McKay S, Hirst SJ, Bertrand-de Haas M, et al. Tumor necrosis factor-α enhances mRNA expression and secretion of interleukin-6 in cultured human airway smooth muscle cells. Am J Respir Cell Mol Biol 23:103-111, 2000.
39. Ammit AJ, Lazaar AL, Irani C, et al. Tumor necrosis factor-α- induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: Modulation by glucocorticoids and β-agonists. Am J Respir Cell Mol Biol 26:465-474, 2002.
40. Barnes PJ, and Karin M. Nuclear factor-κB - A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071, 1997.
41. Amrani Y, Lazaar AL, and Panettieri RA Jr. Up-regulation of ICAM-1 by cytokines in human tracheal smooth muscle cells involves an NF-κB- dependent signaling pathway that is only partially sensitive to dexamethasone. J Immunol 163:2128-2134, 1999.
42. Belvisi MG, Saunders MA, Haddad E-B, et al. Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: Novel inflammatory role of this cell type. Br J Pharmacol 120:910-916, 1997.
43. Pang L, and Knox AJ. Effect of interleukin-1β, tumour necrosis factor-α and interferon-γ on the induction of cyclo-oxygenase-2 in cultured human airway smooth muscle cells. Br J Pharmacol 121:579-587, 1997.
44. Tliba O, Cidlowski JA, and Amrani Y. CD38 expression is insensitive to steroid action in cells treated with tumor necrosis factor-alpha and interferon-gamma by a mechanism involving the up-regulation of the glucocorticoid receptor beta isoform. Mol Pharmacol 69:588-596, 2006.
45. Sukkar MB, Issa R, Xie S, et al. Fractalkine/CX3CL1 production by human airway smooth muscle cells: Induction by IFN-gamma and TNF-alpha and regulation by TGF-beta and corticosteroids. Am J Physiol (Lung Cell Mol Physiol) 287:L1230-L1240, 2004.
46. Sukkar MB, Xie S, Khorasani NM, et al. Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. J Allergy Clin Immunol 118:641-648, 2006.
47. Leung DY, Hamid Q, Vottero A, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 186:1567-1574, 1997.
48. Christodoulopoulos P, Leung DY, Elliott MW, et al. Increased number of glucocorticoid receptor-beta-expressing cells in the airways in fatal asthma. J Allergy Clin Immunol 106:479-484, 2000.
49. Oakley RH, Sar M, and Cidlowski JA. The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem 271:9550-9559, 1996.
50. Pujols L, Mullol J, Torrego A, et al. Glucocorticoid receptors in human airways. Allergy 59:1042-1052, 2004.
51. Tliba O, Damera G, Banerjee A, et al. Cytokines induce an early steroid resistance in airway smooth muscle cells: Novel role of interferon regulatory factor-1. Am J Respir Cell Mol Biol 38:463-472, 2008.
52. Kroger A, Koster M, Schroeder K, et al. Activities of IRF-1. J Interferon Cytokine Res 22:5-14, 2002.
53. Nakao F, Ihara K, Kusuhara K, et al. Association of IFN-gamma and IFN regulatory factor 1 polymorphisms with childhood atopic asthma. J Allergy Clin Immunol 107:499-504, 2001.
54. Mamane Y, Heylbroeck C, Genin P, et al. Interferon regulatory factors: The next generation. Gene 237:1-14, 1999.
55. Yamada K, Elliott WM, Hayashi S, et al. Latent adenoviral infection modifies the steroid response in allergic lung inflammation. J Allergy Clin Immunol 106:844-851, 2000.